News

The Phase 2 study is designed to compare MDV3100 with bicalutamide – a commonly used anti-androgen, and is expected to enroll approximately 370 patients in North America and

In the first of a two segment Phase 2a trial, 64 patients were enrolled and randomised to receive three doses of ACH-1625 given once daily (200mg, 400mg or

The registration dossier of Montelukast Sodium OSF will be primarily based on pharmacokinetic studies, without the need for clinical efficacy trials. The company claims that Montelukast Sodium OSF

Amgen claims that Vectibix, in conjuction with chemotherapy, offers an an important treatment option for patients with wild-type KRAS mCRC. Accoding to the company, the results from the

BioClinica said the new EDA will collect planning information from all of Millennium’s Optimizer-simulated protocols in a central repository and provide an enterprise-wide view of the demand over

The company has posted net income of $13.1m, an increase of 42%, as compared to the net income of $9.2m for the year ago period. Gross profit was

Oracle Health Sciences Enterprise Healthcare Analytics suite and Oracle Healthcare Master Person Index – along with Oracle Fusion Middleware components and Oracle Database 11g have been selected by

Hamamatsu Photonics claims that its new product provides high resolution, high sensitivity and high speed imaging for advanced applications. The camera contains back-thinned EMCCD with Peak Quantum Efficiency

Nile intends to develop Cenderitide as an outpatient therapy to be delivered to acutely decompensated heart failure (ADHF) patients continuously for up to 90 days after discharge from